Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines

Dooling, Kathleen L.; Guo, Angela; Patel, Manisha; Lee, Grace M.; Moore, Kelly; Belongia, Edward A.; Harpaz, Rafael

doi:10.15585/mmwr.mm6703a5

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines

Jan 26 2018
By Dooling, Kathleen L. ; Guo, Angela ; Patel, Manisha ; ...
http://dx.doi.org/10.15585/mmwr.mm6703a5
Source: MMWR Morb Mortal Wkly Rep. 67(3):103-108.

[PDF-114.29 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

MMWR Morb Mortal Wkly Rep
Personal Author:

Dooling, Kathleen L. ; Guo, Angela ; Patel, Manisha ; Lee, Grace M. ; Moore, Kelly ; ... More +

Dooling, Kathleen L. ; Guo, Angela ; Patel, Manisha ; Lee, Grace M. ; Moore, Kelly ; Belongia, Edward A. ; Harpaz, Rafael Less -
Corporate Authors:

United States. Advisory Committee on Immunization Practices.
Description:

On October 20, 2017, Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline, [GSK] Research Triangle Park, North Carolina), a 2-dose, subunit vaccine containing recombinant glycoprotein E in combination with a novel adjuvant (AS01|), was approved by the Food and Drug Administration for the prevention of herpes zoster in adults aged ≥50 years. The vaccine consists of 2 doses (0.5 mL each), administered intramuscularly, 2-6 months apart (1). On October 25, 2017, the Advisory Committee on Immunization Practices (ACIP) recommended the recombinant zoster vaccine (RZV) for use in immunocompetent adults aged ≥50 years.

Published also as: Am J Transplant. 2018 Mar;18(3):756-762. doi: 10.1111/ajt.14683. (PMID: 29462512).
Subjects:

[+]

Advisory Committees Aged Full Report Herpes Zoster Herpes Zoster Vaccine Humans Immunization Schedule Immunocompetence Middle Aged Practice Guidelines As Topic Vaccines, Attenuated Vaccines, Synthetic
Source:

MMWR Morb Mortal Wkly Rep. 67(3):103-108. ; Published also as: Am J Transplant. 2018 Mar;18(3):756-762. doi: 10.1111/ajt.14683. (PMID: 29462512).

MMWR Morb Mortal Wkly Rep. 67(3):103-108. ; Published also as: Am J Transplant. 2018 Mar;18(3):756-762. doi: 10.1111/ajt.14683. (PMID: 29462512). Less -
Pubmed ID:

29370152
Pubmed Central ID:

PMC5812314
Document Type:

Journal Article
Name as Subject:

United States. Food and Drug Administration. ; United States. Food and Drug Administration.

United States. Food and Drug Administration. ; United States. Food and Drug Administration. Less -
Place as Subject:

United States
Location:

North America
Volume:

67
Issue:

3
Collection(s):

Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:

[+]

urn:sha256:244c8cc95fdcaac264cb09a773961e31c57850a61add8e3b9a9254d39d446f3e
Download URL:

https://stacks.cdc.gov/view/cdc/55095/cdc_55095_DS1.pdf
File Type:

mm6703a5.nxml

xml

More +